Good point. Maybe they do a sort of two-step like in some of the trials where they had a few of the trial subjects undergo tests for questions of pharmacokinetics and pharmacodynamics and then, I think, everyone participated in the whole trial. Or else like you said, they're already comfortable with their data for dosage across a range of even untested indications.
News 
Market Data 
Discover 
AI
